Mr. Panara et al., Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects, J PHARM EXP, 290(1), 1999, pp. 276-280
Citations number
35
Categorie Soggetti
Pharmacology & Toxicology
Journal title
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
We evaluated whether therapeutic blood levels of meloxicam are associated w
ith selective inhibition of monocyte cyclooxygenase (COX)-2 in vitro and ex
vivo. Concentration-response curves for the inhibition of monocyte COX-2 a
nd platelet COX-1 were obtained in vitro after the incubation of meloxicam
with whole blood samples. Moreover, 11 healthy volunteers received placebo
or 7.5 or 15 mg/day meloxicam, each treatment for 7 consecutive days, accor
ding to a randomized, double-blind, crossover design. Before dosing and 24
h after the seventh dose of each regimen, heparinized whole blood samples w
ere incubated with lipopolysaccharide (10 mu g/ml) for 24 h at 37 degrees C
, and prostaglandin E-2 was measured in plasma as an index of monocyte COX-
2 activity. The production of thromboxane B-2 in whole blood allowed to clo
t at 37 degrees C for 60 min was assessed as an index of platelet COX-1 act
ivity. The administration of placebo did not significantly affect plasma pr
ostaglandin E-2 (21.3 +/- 7.5 versus 19.1 +/- 4 ng/ml, mean +/- S.D., n = 1
1) or serum thromboxane B-2 (426 +/- 167 versus 425 +/- 150 ng/ml) levels.
In contrast, the administration of 7.5 and 15 mg of meloxicam caused dose-d
ependent reductions in monocyte COX-2 activity by 51% and 70%, respectively
, and in platelet COX-1 activity by 25% and 35%, respectively. Although the
IC50 value of meloxicam for inhibition of COX-1 was 10-fold higher than th
e IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate
to clearly separate the effects of meloxicam on the two isozymes after ora
l dosing as a function of the daily dose and interindividual variation in s
teady-state plasma levels.